Private biotechs received almost $4bn in venture financing in the third quarter, as the healthy financing climate showed few signs of deteriorating.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
Which groups might Boston Scientific bolt on next?
Sequencing data is all well and good, but what does it mean?
The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.